Blood-based biomarkers are reshaping our understanding of neurodegenerative dementia in ways you might not expect.
In this video, I explore the range of biomarkers, including phosphorylated tau, and discuss their role in distinguishing different forms of dementia.
We also delve into the evolving significance of genetic tests, such as apolipoprotein E, and why theyre now more commonly used in clinical settings.
What new insights could these biomarkers unveil about the future of dementia treatment?
Amy E. Sandersis a neurologist.
SUBSCRIBE TO THE PODCAST https://www.kevinmd.com/podcast
